CA2172159A1 - Improved pharmaceutical formulation - Google Patents
Improved pharmaceutical formulationInfo
- Publication number
- CA2172159A1 CA2172159A1 CA002172159A CA2172159A CA2172159A1 CA 2172159 A1 CA2172159 A1 CA 2172159A1 CA 002172159 A CA002172159 A CA 002172159A CA 2172159 A CA2172159 A CA 2172159A CA 2172159 A1 CA2172159 A1 CA 2172159A1
- Authority
- CA
- Canada
- Prior art keywords
- compositions
- cyclodextrin
- ulceration
- irritation
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Abstract
Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxyc drugs such as antibiotic, anti-fungal and anti-neoplastic drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation.
Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and/or irritation when administering the compositions according to the invention are also disclosed and claimed.
Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and/or irritation when administering the compositions according to the invention are also disclosed and claimed.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11672493A | 1993-09-03 | 1993-09-03 | |
US116,724 | 1993-09-03 | ||
US297,249 | 1994-08-26 | ||
US08/297,249 US5602112A (en) | 1992-06-19 | 1994-08-26 | Pharmaceutical formulation |
PCT/US1994/009879 WO1995006485A1 (en) | 1993-09-03 | 1994-09-02 | Improved pharmaceutical formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2172159A1 true CA2172159A1 (en) | 1995-03-09 |
CA2172159C CA2172159C (en) | 2003-07-29 |
Family
ID=26814548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002172159A Expired - Fee Related CA2172159C (en) | 1993-09-03 | 1994-09-02 | Improved pharmaceutical formulation |
Country Status (13)
Country | Link |
---|---|
US (6) | US5602112A (en) |
EP (1) | EP0717638B1 (en) |
JP (1) | JPH09502185A (en) |
AT (1) | ATE214290T1 (en) |
AU (1) | AU7718694A (en) |
CA (1) | CA2172159C (en) |
DE (1) | DE69430126T2 (en) |
DK (1) | DK0717638T3 (en) |
ES (1) | ES2171462T3 (en) |
HU (1) | HUT73778A (en) |
IL (1) | IL110825A0 (en) |
PT (1) | PT717638E (en) |
WO (1) | WO1995006485A1 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
PT689438E (en) * | 1993-03-26 | 2003-10-31 | Franciscus Wilhelmus He Merkus | PHARMACEUTICAL COMPOSITIONS FOR INTROMASSAL ADMINISTRATION OF APOMORPHINE |
ATE302599T1 (en) | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | PREPARATIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISEASES OF THE BODY PASSAGES |
US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
CA2275889C (en) | 1996-12-30 | 2008-03-18 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
HUP9701945A3 (en) * | 1997-11-10 | 2000-04-28 | Hexal Ag | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
GB9921954D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties |
GB9921958D0 (en) * | 1999-09-16 | 1999-11-17 | Pharmacia & Upjohn Spa | Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins |
SI1278549T1 (en) | 2000-05-02 | 2009-04-30 | Theravance Inc | Composition containing a cyclodextrin and a glycopeptide antibiotic |
WO2001083520A2 (en) * | 2000-05-02 | 2001-11-08 | Theravance,Inc | Polyacid glycopeptide derivatives |
UA75083C2 (en) * | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Derivatives of glycopeptidephosphonates |
AU2001259816A1 (en) | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
ES2302733T3 (en) * | 2000-06-22 | 2008-08-01 | Theravance, Inc. | CARBOXI-SACARIDS DERIVATIVES OF GLUCOPEPTIDE. |
US6872804B2 (en) * | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
US6468989B1 (en) * | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
PE20020300A1 (en) * | 2000-08-22 | 2002-05-10 | Pharmacia Corp | COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD |
IT1318689B1 (en) * | 2000-09-12 | 2003-08-27 | Pharmacia & Upjohn Spa | USE OF ARGININE IN THE PREPARATION OF A MEDICATION FOR THE PREPARATION AND TREATMENT OF THE SIDE EFFECTS ASSOCIATED WITH |
US6884885B2 (en) * | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
US20030003048A1 (en) * | 2001-04-26 | 2003-01-02 | Chun Li | Diagnostic imaging compositions, their methods of synthesis and use |
US6528076B2 (en) | 2001-07-06 | 2003-03-04 | Magic Herb Corp. | Topical compositions and methods for treating pain |
GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
US6828311B2 (en) | 2002-05-29 | 2004-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Formulation for the parenteral application of a sodium channel blocker |
NZ538584A (en) * | 2002-09-05 | 2007-05-31 | Bharat Serums & Vaccines Ltd | Stable liquid composition of oxazaphosphorine, mesna and etherified beta-cyclodextrin |
US7157446B2 (en) * | 2003-05-02 | 2007-01-02 | Bristol Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
LT1713504T (en) * | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms |
ATE475408T1 (en) * | 2005-10-14 | 2010-08-15 | Janssen Pharmaceutica Nv | FORMULATIONS OF TIPIFARNIB FOR INTRAVENOUS ADMINISTRATION |
CN100411688C (en) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | Medicine composition containing cyclodextrin/polyene taxol and its prepn process |
CN100486645C (en) | 2006-09-12 | 2009-05-13 | 南京师范大学 | Medicine composition containing cyclodextrin included taxol and its preparation process |
KR20110098009A (en) | 2006-10-20 | 2011-08-31 | 이코스 코포레이션 | Compositions of chk1 inhibitors and cyclodextrin |
US20100021400A1 (en) * | 2008-04-25 | 2010-01-28 | Rhode Island Hospital | Active Sunscreen Composition |
ES2525257T3 (en) | 2009-02-25 | 2014-12-19 | Supratek Pharma, Inc. | Compositions of cyclopolysaccharide and bendamustine |
CN102458114A (en) | 2009-05-29 | 2012-05-16 | 锡德克斯药物公司 | Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same |
US11020363B2 (en) | 2009-05-29 | 2021-06-01 | Cydex Pharmaceuticals, Inc. | Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same |
US20110015245A1 (en) * | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
US8389558B2 (en) * | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
TWI438009B (en) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | Taxane pro-emulsion formulations and methods making and using the same |
SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
LT2758052T (en) * | 2011-09-18 | 2018-04-10 | Euro-Celtique S.A. | Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide |
AR092790A1 (en) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
WO2015017803A1 (en) * | 2013-08-02 | 2015-02-05 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
WO2015061206A2 (en) | 2013-10-21 | 2015-04-30 | North Carolina State University | Methods and constructs for compound delivery |
RU2587716C2 (en) * | 2014-01-14 | 2016-06-20 | Борис Игоревич Круглый | Stable pharmaceutical composition based on actinomycin d for injections |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5735189B2 (en) * | 1972-01-06 | 1982-07-27 | ||
US4024223A (en) * | 1972-11-11 | 1977-05-17 | Teijin Limited | Stripe composition and method of reducing smell associated therewith |
JPS53136513A (en) * | 1977-05-06 | 1978-11-29 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin-x-related compounds |
HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
JPS54115368A (en) * | 1978-03-01 | 1979-09-07 | Ono Pharmaceut Co Ltd | Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent |
DE2912409A1 (en) * | 1978-03-31 | 1979-10-11 | Ono Pharmaceutical Co | 6,9 METHANO PGI LOW 2 ANALOGS |
US4352793A (en) * | 1979-04-26 | 1982-10-05 | Sumitomo Chemical Company, Limited | Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin |
JPS6033430B2 (en) * | 1980-05-12 | 1985-08-02 | 小野薬品工業株式会社 | Prostaglandin-like compounds |
EP0056995B1 (en) * | 1981-01-23 | 1986-03-26 | The Wellcome Foundation Limited | Chemical complex |
US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
JPS5813541A (en) * | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | Cyclodextrin clathrate compound of eicosapentaenoic acid or docosahexaenoic acid |
JPS5838250A (en) * | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | Composite |
JPS58126810A (en) * | 1981-12-24 | 1983-07-28 | Kaken Pharmaceut Co Ltd | Ophthalmic anti-inflammatory solution and preparation thereof |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
JPS58177949A (en) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | Clathrate compound of lankacidin-group antibiotic substance |
US4659696A (en) * | 1982-04-30 | 1987-04-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition and its nasal or vaginal use |
DE3315356A1 (en) * | 1982-04-30 | 1983-11-17 | Ono Pharmaceutical Co. Ltd., Osaka | USE OF PROSTAGLANDINE ANALOGS |
US4425336A (en) * | 1982-05-24 | 1984-01-10 | Key Pharmaceuticals, Inc. | 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes |
US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
JPS5910510A (en) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | Low irritant tiamulin injection |
JPS5920230A (en) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | Drug containing piruprophen |
HU190818B (en) * | 1982-11-09 | 1986-11-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
JPS6025967A (en) * | 1983-07-21 | 1985-02-08 | Eisai Co Ltd | Tripamide clathrate compound |
US4751095A (en) * | 1983-07-28 | 1988-06-14 | Karl Curtis L | Aspartame stabilization with cyclodextrin |
JPS6081166A (en) * | 1983-10-11 | 1985-05-09 | Fujisawa Pharmaceut Co Ltd | Beta-cyclodextrin clathrate compound of 2-nitroxymethyl-6- chloropyridine and production thereof |
IT1196033B (en) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | COMPOUND WITH ANTI-INFLAMMATORY ACTIVITY OBTAINED BY COMPLEXATION WITH BETA-CYCLODEXTRINE AND RELATED PHARMACEUTICAL FORMULATIONS |
US4675395A (en) * | 1984-03-14 | 1987-06-23 | Seiwa Technological Laboratories Limited | Cyclodextrin inclusion compound and process for its preparation |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPS61207380A (en) * | 1985-03-11 | 1986-09-13 | Taiyo Yakuhin Kogyo Kk | Oral preparation of mobenzoxamine |
JPS61286318A (en) * | 1985-06-13 | 1986-12-16 | Ichiro Shibauchi | Production of bathing agent |
US4663316A (en) * | 1985-06-28 | 1987-05-05 | Warner-Lambert Company | Antibiotic clathrates and pharmaceutical compositions thereof |
US4728509A (en) * | 1985-08-19 | 1988-03-01 | Takeda Chemical Industries, Ltd. | Aqueous liquid preparation |
US4623641A (en) * | 1985-09-09 | 1986-11-18 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
ATE196426T1 (en) * | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | CYCLODEXTRIN COMPOSITION CONTAINING FUMAGILLOL DERIVATIVES |
JP3176716B2 (en) * | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | Poorly water-soluble drug composition having improved solubility |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
JPH06157330A (en) * | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | Cyclodextrin clathrate of taxol, it production and use thereof |
-
1994
- 1994-08-26 US US08/297,249 patent/US5602112A/en not_active Expired - Lifetime
- 1994-08-30 IL IL11082594A patent/IL110825A0/en unknown
- 1994-09-02 WO PCT/US1994/009879 patent/WO1995006485A1/en active IP Right Grant
- 1994-09-02 PT PT94927983T patent/PT717638E/en unknown
- 1994-09-02 AU AU77186/94A patent/AU7718694A/en not_active Abandoned
- 1994-09-02 HU HU9600612A patent/HUT73778A/en unknown
- 1994-09-02 JP JP7508268A patent/JPH09502185A/en active Pending
- 1994-09-02 ES ES94927983T patent/ES2171462T3/en not_active Expired - Lifetime
- 1994-09-02 DE DE69430126T patent/DE69430126T2/en not_active Expired - Fee Related
- 1994-09-02 DK DK94927983T patent/DK0717638T3/en active
- 1994-09-02 AT AT94927983T patent/ATE214290T1/en active
- 1994-09-02 CA CA002172159A patent/CA2172159C/en not_active Expired - Fee Related
- 1994-09-02 EP EP94927983A patent/EP0717638B1/en not_active Expired - Lifetime
-
1997
- 1997-02-03 US US08/790,223 patent/US5804568A/en not_active Expired - Lifetime
-
1998
- 1998-08-28 US US09/143,412 patent/US6048845A/en not_active Expired - Lifetime
-
1999
- 1999-07-02 US US09/347,096 patent/US6218374B1/en not_active Expired - Fee Related
-
2000
- 2000-10-05 US US09/684,375 patent/US6284747B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 US US09/938,473 patent/US6583125B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6218374B1 (en) | 2001-04-17 |
AU7718694A (en) | 1995-03-22 |
HUT73778A (en) | 1996-09-30 |
US20020058634A1 (en) | 2002-05-16 |
DK0717638T3 (en) | 2002-07-01 |
DE69430126T2 (en) | 2002-08-01 |
CA2172159C (en) | 2003-07-29 |
HU9600612D0 (en) | 1996-05-28 |
US6583125B2 (en) | 2003-06-24 |
ATE214290T1 (en) | 2002-03-15 |
JPH09502185A (en) | 1997-03-04 |
US6048845A (en) | 2000-04-11 |
EP0717638A1 (en) | 1996-06-26 |
US5602112A (en) | 1997-02-11 |
US5804568A (en) | 1998-09-08 |
IL110825A0 (en) | 1995-05-26 |
ES2171462T3 (en) | 2002-09-16 |
PT717638E (en) | 2002-07-31 |
WO1995006485A1 (en) | 1995-03-09 |
DE69430126D1 (en) | 2002-04-18 |
EP0717638B1 (en) | 2002-03-13 |
US6284747B1 (en) | 2001-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2172159A1 (en) | Improved pharmaceutical formulation | |
FR2708608B1 (en) | N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them. | |
CA2159450A1 (en) | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors | |
RU94043809A (en) | Medicinal composition for release-control | |
EP0214647A3 (en) | Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes | |
CA2121345A1 (en) | Lipophilic Oligosaccharide Antibiotic Salt Compositions | |
AU8188691A (en) | The use of inositoltrisphosphate for the preparing of medicaments | |
WO1999012532A3 (en) | Piperidine derivatives against malaria | |
KR987000322A (en) | Novel Anthracycline Compound Derivatives and Pharmaceutical Formulations Containing the Same (NOVEL ANTHRACYCLINE COMPOUND DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME) | |
EP1200095B1 (en) | Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances | |
WO1999048503A1 (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
CA2173147A1 (en) | Anti-obesity agent | |
CA2307788A1 (en) | 2-halo-6-o-substituted ketolide derivatives | |
CA2140927A1 (en) | Platelet aggregation inhibitors | |
CA2100126A1 (en) | 5,10-Methylenetetrahydrofolic Acid-Cyclodextrin Inclusion Compounds | |
AU7694896A (en) | Prompt-release pharmaceutical compositions | |
EP0412940A3 (en) | Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure | |
WO1996023771A3 (en) | Platelet aggregation inhibitors | |
WO2002028389A1 (en) | Antitumor therapy comprising distamycin derivatives | |
WO1999005103A3 (en) | 2o(s)-7-ethyl-9-(n-methyl-n-phenyl)amidino-camptothecin, its preparation and its use as antitumor agent | |
CA2129676A1 (en) | Dextromethorphan Antitussive Compositions | |
Scheife et al. | Bacampicillin hydrochloride: chemistry, pharmacology, and clinical use | |
BG103985A (en) | Multicyclic derivatives of erythromycin | |
CA2206333A1 (en) | Novel anthracycline compound derivative and pharmaceutical preparation containing the same | |
CA2563965A1 (en) | 6-0-substituted ketolides having antibacterial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |